These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22311627)

  • 41. Influenza virus surveillance by the Instituto Adolfo Lutz, influenza season 2014: antiviral resistance.
    Santos KC; Silva DB; Benega MA; Paulino Rde S; Silva ER; Pereira Ddos S; Mussi AD; Silva VC; V Gubareva L; Paiva TM
    Rev Inst Med Trop Sao Paulo; 2015; 57(1):92. PubMed ID: 25651335
    [No Abstract]   [Full Text] [Related]  

  • 42. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
    Leyva-Grado VH; Tan GS; Leon PE; Yondola M; Palese P
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4162-72. PubMed ID: 25941218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Global transmission of oseltamivir-resistant influenza.
    Moscona A
    N Engl J Med; 2009 Mar; 360(10):953-6. PubMed ID: 19258250
    [No Abstract]   [Full Text] [Related]  

  • 44. 10 Years on, the world still learns from SARS.
    Arnold C
    Lancet Infect Dis; 2013 May; 13(5):394-5. PubMed ID: 23755396
    [No Abstract]   [Full Text] [Related]  

  • 45. Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2.
    Saito R; Sakai T; Sato I; Sano Y; Oshitani H; Sato M; Suzuki H
    J Clin Microbiol; 2003 May; 41(5):2164-5. PubMed ID: 12734269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The epidemiology and spread of drug resistant human influenza viruses.
    Hurt AC
    Curr Opin Virol; 2014 Oct; 8():22-9. PubMed ID: 24866471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathogenesis of avian flu H5N1 and SARS.
    Peiris M
    Novartis Found Symp; 2006; 279():56-60; discussion 60-5, 216-9. PubMed ID: 17278385
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-influenza virus effects of cocoa.
    Kamei M; Nishimura H; Takahashi T; Takahashi N; Inokuchi K; Mato T; Takahashi K
    J Sci Food Agric; 2016 Mar; 96(4):1150-8. PubMed ID: 25847473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular epidemiology of influenza A virus infection among hospitalized children in Vietnam during post-pandemic period.
    Tran DN; Pham TM; Ha MT; Hayakawa S; Mizuguchi M; Ushijima H
    J Med Virol; 2015 Jun; 87(6):904-12. PubMed ID: 25648607
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.
    Stephenson I; Democratis J; Lackenby A; McNally T; Smith J; Pareek M; Ellis J; Bermingham A; Nicholson K; Zambon M
    Clin Infect Dis; 2009 Feb; 48(4):389-96. PubMed ID: 19133796
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the pathology caused by H1N1, H5N1, and H3N2 influenza viruses.
    Guarner J; Falcón-Escobedo R
    Arch Med Res; 2009 Nov; 40(8):655-61. PubMed ID: 20304252
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir.
    Koudstaal W; Koldijk MH; Brakenhoff JP; Cornelissen LA; Weverling GJ; Friesen RH; Goudsmit J
    J Infect Dis; 2009 Dec; 200(12):1870-3. PubMed ID: 19911992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The influenza pandemics:learned lessons].
    Reina J
    Rev Esp Quimioter; 2009 Nov; 22 Suppl 1():2-4. PubMed ID: 20084338
    [No Abstract]   [Full Text] [Related]  

  • 55. Comparison of the effectiveness of Zanamivir and Oseltamivir against influenza A/H1N1, A/H3N2, and B.
    Kawai N; Ikematsu H; Iwaki N; Maeda T; Kawashima T; Hirotsu N; Kashiwagi S
    Clin Infect Dis; 2009 Apr; 48(7):996-7. PubMed ID: 19260819
    [No Abstract]   [Full Text] [Related]  

  • 56. Human Anti-neuraminidase Antibodies Reduce Airborne Transmission of Clinical Influenza Virus Isolates in the Guinea Pig Model.
    Tan J; O'Dell G; Hernandez MM; Sordillo EM; Kahn Z; Kriti D; van Bakel H; Ellebedy AH; Wilson PC; Simon V; Krammer F; McMahon M
    J Virol; 2022 Jan; 96(2):e0142121. PubMed ID: 34669506
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 18th International Conference on Antiviral Research. Respiratory viruses.
    Kibble A
    IDrugs; 2005 Jun; 8(6):465-6. PubMed ID: 15906188
    [No Abstract]   [Full Text] [Related]  

  • 58. Recommended composition of influenza virus vaccines for use in the 2009 southern hemisphere influenza season.
    Wkly Epidemiol Rec; 2008 Oct; 83(41):366-72. PubMed ID: 18846716
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
    Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
    Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Seasonal Influenza A H1N1pdm09 Virus and Severe Outcomes: A Reason for Broader Vaccination in Non-Elderly, At-Risk People.
    Minchole E; Figueredo AL; Omeñaca M; Panadero C; Royo L; Vengoechea JJ; Fandos S; de Pablo F; Bello S
    PLoS One; 2016; 11(11):e0165711. PubMed ID: 27832114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.